PBYI Puma Biotechnology
- 5.020
- +0.140+2.87%
- 5.120
- +0.100+1.99%
Puma Biotechnology News
What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 2, 2024, following the release of its first quarter 2024 financial
Puma Biotechnology (NASDAQ:PBYI) Shareholders Have Earned a 93% Return Over the Last Year
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on April 2, 2024, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit
Do Puma Biotechnology's (NASDAQ:PBYI) Earnings Warrant Your Attention?
Puma Biotechnology Plans to Start Breast Cancer Combination Study in Second Half; Shares Rise
Puma Biotechnology (PBYI) said Wednesday that it intends to begin a phase 2 breast cancer study that will evaluate alisertib in combination with endocrine treatment in the second half of 2024. The com
Puma Biotech Cleared to Trial Takeda-partnered Breast Cancer Therapy in U.S.
Does Puma Biotechnology (NASDAQ:PBYI) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is usu
Express News | Puma Biotechnology Announces FDA Allowance To Proceed Under IND For Alisertib In HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company (the Company), has been notified by the U.S. Food and Drug Administration (FDA) that its Investigational New Drug Application (IND) submission has been
10 Health Care Stocks With Whale Alerts In Today's Session
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth.
COIN, HUT and WNW Among Pre-market Losers
Express News | Watching Puma Biotechnology; Traders Circulate Rumor, "Puma Has Been Dismissed As A Plaintiff In Its Case Against AstraZeneca Alleging That Tagrisso Infringes Its Patents Citing Lack Of Standing"
FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study
J&J (JNJ) Secures Full FDA Nod for Rybrevant in Lung Cancer
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Could Be 47% Below Their Intrinsic Value Estimate
Puma Biotechnology Is Maintained at Buy by HC Wainwright & Co.
Puma Biotechnology Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Puma Biotechnology, Lowers Price Target to $7
Puma Biotechnology Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/01/2024 18.24% HC Wainwright & Co. $8 → $7 Maintains Buy 02/13/2024 35.14% HC Wainwright & Co. → $8 Rei
Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 31% Price Boost Is Out Of Tune With Earnings
Despite an already strong run, Puma Biotechnology, Inc. (NASDAQ:PBYI) shares have been powering on, with a gain of 31% in the last thirty days. Looking back a bit further, it's encouraging to see t
Analysis
Price Target
No Data
